Moving iMage Technologies GAAP EPS of $0.02, revenue of $6.1M

Moving iMage Technologies reported Q1 GAAP EPS of $0.02 and revenue of $6.1M, up 8.9% year-over-year. The company noted that the second quarter is typically a slower period for cinema industry investments.

Original reporting
Published Nov 13, 2026, 2:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 2:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$MITQ
Neutral
medium confidence
Mentioned
$MITQ
Relevance
6/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$MITQNeutralLow
01

Why it matters

The disclosed numbers represent the first public reporting of the quarter's results, offering fresh data for traders.

02

Market read

First‑report earnings for a micro‑cap; limited but actionable for niche investors.

03

What to watch

Potential upcoming capital‑intensive projects in the second quarter could strain cash flow despite the modest revenue growth.

Relevance 6/10Novelty 7/10Timing: post‑market release

Background

Moving iMage Technologies (MITQ) issued a brief press release reporting its Q1 GAAP earnings and revenue.

Company-level read

Ticker impact

$MITQNeutralMedium confidence
Context

Q1 GAAP EPS of $0.02 and revenue of $6.1M were disclosed in the company's press release.

Expected impact

likely modest upward pressure as market prices in the earnings beat

Evidence & confidence

Micro‑cap earnings with a small positive surprise typically generate limited but positive price movement.

Market effects

Minimal impact on the broader cinema‑technology sector.

No discernible regional effect.

Limited to investors tracking micro‑cap earnings.

Counterpoint

The earnings beat may be overstated; investors could remain skeptical given the company's small scale.

Key entities

  • Moving iMage Technologies

    Micro‑cap firm providing cinema‑industry technology solutions.

Related articles

$MITQMed

Cinema Solutions Provider Moving iMage Technologies Progresses Toward Profitability, Trimming FY 2026 Net Loss 69% to ($297K) on Net Sales of $17.3M; Hosts…

MOVING iMAGE TECHNOLOGIES INC. (MITQ) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cinema Solutions Provider Moving iMage Technologies Progresses Toward Profitability, Trimming FY 2026 Net Loss 69% to ($297K) on Net Sales of $17.3M; Hosts Investor Call Today at 11am ET Fountain Valley, CA – September 28, 2026 – Moving iMage Technologies, Inc. (NYSE

$NMAXMed

Why Newsmax Stock Popped on Friday

Newsmax (NMAX) shares rose 31% after reporting Q3 revenue of $69M, up 52.5% YoY, and net income of $15.2M. The company cited strong audience engagement and growth in high-margin revenue streams. CEO Christopher Ruddy expects continued growth ahead of the presidential election.

$LUNRMed

What Is Driving Intuitive Machines Stock?

Intuitive Machines (LUNR) shares rose 7.0% on Nov 12, 2026, after reporting Q3 revenue of $269M, beating estimates. The company's loss of $0.10 per share met expectations, while gross margin improved to 26%. Free cash flow turned positive at $33M, a company record. Management raised full-year revenue guidance to $920M-$950M. The stock's performance contrasted with broader industry declines.

$RMIXMedAI 8/10

Suncrete (RMIX) Q3 2026 Earnings Call Transcript

Suncrete (RMIX) reported Q3 2026 revenue of $141M, up 45% QoQ and 163% YoY. Adjusted EBITDA rose 66% QoQ to $22.4M. The company lowered its full-year outlook due to residential construction weakness but remains confident in long-term demand. Acquisition integration is progressing, with North Texas showing margin improvement. Suncrete expects $200M-$250M revenue from 2026 acquisitions in 2027. The company has $206.5M in total liquidity.

$CLLSMed

Cellectis SA (CLLS) (Q3 2026) Earnings Call Highlights: Strategic Shift to Gene

Cellectis SA (CLLS) discussed its strategic shift to gene editing during its Q3 2026 earnings call. Management highlighted the selection of APOC3 over ANGPTL3 for triglyceride reduction, with plans to start Phase 1 dosing by end-2027. The company reported $149M in cash as of September 30, 2026, with a runway into H2 2028. Revenue decreased to $19.9M from $67.4M YoY, while R&D expenses increased to $108.8M from $69.1M, driven by the AstraZeneca collaboration.

$YTRAMed

Yatra Online Inc (YTRA) (Q2 2027) Earnings Call Highlights: Air and Corporate Travel

Yatra Online (YTRA) reported Q2 2027 revenue from operations down 39% YoY to INR2,136M (~$22M) due to lower MICE volumes. Gross margin stayed flat at INR1,255M (~$13M). Adjusted EBITDA swung to negative INR32M (~negative $0.3M). CEO Gupta noted MICE recovery signs, TravelPro and Recap initiatives progress, and AI efficiency gains. Standalone hotels grew 20% YoY. H1 FY27 revenue declined 28% YoY to INR4,015M (~$42M).